Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $8.00 at D. Boral Capital

Reviva Pharmaceuticals (NASDAQ:RVPH) had its price target dropped by D. Boral Capital from $15.00 to $8.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Other research analysts have also issued research reports about the stock. HC Wainwright lowered their price objective on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Friday, January 10th. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. Finally, Roth Mkm assumed coverage on Reviva Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $7.00 target price for the company. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $10.00.

Reviva Pharmaceuticals Stock Down 5.6 %

Shares of NASDAQ RVPH opened at $0.95 on Tuesday. The firm has a market cap of $31.90 million, a price-to-earnings ratio of -0.86 and a beta of -0.09. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $4.28. The business’s 50 day moving average is $1.51 and its two-hundred day moving average is $1.47.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Analysts anticipate that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of RVPH. Geode Capital Management LLC lifted its holdings in Reviva Pharmaceuticals by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after buying an additional 42,376 shares during the last quarter. EMC Capital Management lifted its stake in Reviva Pharmaceuticals by 142.0% during the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after purchasing an additional 26,134 shares during the last quarter. Drive Wealth Management LLC purchased a new stake in Reviva Pharmaceuticals during the fourth quarter worth approximately $36,000. Ameriprise Financial Inc. acquired a new position in Reviva Pharmaceuticals in the fourth quarter valued at approximately $84,000. Finally, Tang Capital Management LLC purchased a new position in Reviva Pharmaceuticals in the fourth quarter valued at approximately $308,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.